|
|
|
|
| Advertisement |
 |
|
|
| Therapeutic Specific Areas |
|
|
| Advertisement |
 |
Deloitte's 2019 Life Sciences accounting and financial reporting update
Insights on new accounting standards and more
A year of major change for life sciences companies is underway. Deloitte's latest update on life sciences financial reporting explains what accounting departments need to know to keep up in a rapidly evolving environment.
 Download the full report here
|
|
| Cybersecurity |
 |
|
What Has Pharma Learned from the Merck Cyber Attack
|
Cybersecurity is a pressing issue to pharmaceutical businesses in particular, for a significant number of reasons. In June of 2017, word first broke that Merck was just one of more than a dozen businesses that were hit with a massive ransomware attack that ultimately ended up affecting organizations all over the world.
... /Read more/ |
|
|
|
ADVERTISEMENT
|
|
| Advertisement |
 |
|
|
| Regulatory Affairs |
 |
|
How Fast are the FDA Fast Lanes?
|
There's been a lot of talk about speeding up drug approval at FDA, especially from President Trump. So just how fast can approval be? In another in a series to explore the expedited FDA approvals, Leela Barham takes a look at the speed of approval for each of FDA's expedited development and review methods.
... /Read more/ |
|
|
| Advertisement |
Patient Adherence: A Hard Pill to Swallow?
On Demand
 Learn More
|
|
| Digital Medicine |
|
|
The Pharm Exec Podcast: Episode 28
|
Pharm Exec editors speak with Bill Carson, President & CEO of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Kabir Nath, President & CEO of Otsuka North America Pharmaceuticals about digital medicine, mental health therapies, and creating a smooth and collaborative relationship between R&D and commercial.
... /Read more/ |
|
|
| Industry Influence |
 |
|
KOLs: An Endangered Buzzword |
KOLs have traditionally exerted their influence through research and publication on drug safety and efficacy, but now share the stage with other important measures.
... /Read more/ |
|
|
|
|
|
|
